**Virologica Sinica**

**Supplementary Data**

**Myocardial injury and related mortality in hospitalized patients with COVID-19 during the** **Omicron pandemic: new perspectives and insights**

**Wu Hea,b,1, Ke Xu a,b,1, Li Nia,b, Junfang Wua,b, Yuxuan Zhanga,b, Kun Miaoa,b, Luyun Wanga,b, Dao Wen Wanga,b,\***

*aDivision of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China*

*bHubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, 430030, China*

\*Corresponding author.

*Email address*: dwwang@tjh.tjmu.edu.cn (D.W. Wang)

1Wu He and Ke Xu contributed equally to this work.

**Supplementary Table S1** Clinical Characteristics of COVID-19 Patients with Angiotensin II Measurement

|  |  |  |
| --- | --- | --- |
|  | Normal control (n = 30) | COVID-19 patients with Omicron infection |
| Total COVID-19 patients (n = 34) | Myocardial injury group (n = 12) | No injury group (n = 22) |
| Sex (%) |  |  |  |  |
| Male | 20 (66.7) | 20 (58.8) | 5 (41.7) | 15 (68.2) |
| Female | 10 (33.3) | 14 (41.2) | 7 (58.3) | 7 (31.2) |
| Age-years |  |  |  |  |
| Mean±SEM | 44.70 ± 2.14 | 46.91 ± 2.17 | 48.08 ± 4.73 | 46.27 ± 2.24 |
| Median (IQR) | 42 (33–57) | 49 (36–57) | 50 (33–59) | 49 (37–53) |
| Range | 26–60 | 27–81 | 27–81 | 31–64 |
| Hospitalization days |  |  |  |  |
| Mean ± SEM | - | 19.94 ± 2.12 | 22.83 ± 3.98 | 18.36 ± 2.46 |
| Median (IQR) | - | 17 (13–24) | 18 (14–35) | 16 (12–22) |
| Range | - | 4–48 | 4–47 | 4–48 |
| Original comorbidities (%) |  |  |  |  |
| Hypertension (%) | 4 (13.3) | 13 (38.2) | 6 (50.0) | 7 (31.8) |
| CHD (%) | 1 (3.3) | 2 (5.9) | 1 (8.3) | 1 (4.5) |
| CHF (%) | 0 (0) | 2 (5.9) | 1 (8.3) | 1 (4.5) |
| T2D (%) | 3 (10.0) | 7 (20.6) | 2 (16.7) | 5 (22.7) |
| CKD (%) | 1 (3.3) | 2 (5.9) | 1 (8.3) | 1 (4.5) |
| Tumor (%) | 0 (0) | 3 (8.8) | 1 (8.3) | 2 (9.1) |

CHD, coronary heart disease; T2D, type 2 diabetes; CKD, chronic kidney disease; SEM, standard error of mean; IQR, interquartile range.

****

**Supplementary Fig. S1.** The Kaplan-Meier survival curve of in-hospital mortality for COVID-19 patients with different levels of hs-cTnI in myocardial injury group (**A**) and no injury group (**B**). hs-cTnI have been binary classified by the 50th percentile as the cut-off value (hs-cTnI cut-off value in myocardial injury group: 47.15 pg/mL; hs-cTnI cut-off value in no injury group: 4.55 pg/mL;).

****

**Supplementary Fig. S2.** Comparison of IL-1β, IL-6, IL-10 and TNF-α levels between surviving and died COVID-19 patients in myocardial injury group.Data are presented as the mean ± standard deviation, and statistical analyses were performed using a *t*-test. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001

****

**Supplementary Fig. S3.** The Kaplan-Meier survival curve of in-hospital mortality for COVID-19 patients with/without antiplatelet drugs in myocardial injury group.